" class="no-js "lang="en-US"> Nosopharm - Medtech Alert
Friday, September 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Nosopharm | Pharmtech Focus

Nosopharm

About Nosopharm

Nosopharm

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

Related Story

Appointments

 Nosopharm Welcomes New Members To Supervisory Board | Pharmtech Focus

Nosopharm Welcomes New Members To Supervisory Board

July 12 2022

Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, […]

Drug Development

 Nosopharm and GNA NOW Announce Positive Results for the Late Preclinical Development of the First-in-class Antibiotic NOSO-502 | Pharmtech Focus

Nosopharm and GNA NOW Announce Positive Results for the Late Preclinical Development of the First-in-class Antibiotic NOSO-502

June 9 2022

Nosopharm, a biotechnology company specialized in exploring unconventional sources of antibiotics to discover new drugs […]